M

Mabwell Shanghai Bioscience Co Ltd
SSE:688062

Watchlist Manager
Mabwell Shanghai Bioscience Co Ltd
SSE:688062
Watchlist
Price: 22.92 CNY -2.51%
Market Cap: 9.2B CNY
Have any thoughts about
Mabwell Shanghai Bioscience Co Ltd?
Write Note

Mabwell Shanghai Bioscience Co Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mabwell Shanghai Bioscience Co Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
M
Mabwell Shanghai Bioscience Co Ltd
SSE:688062
Cash from Operating Activities
-ÂĄ782.7m
CAGR 3-Years
-15%
CAGR 5-Years
-38%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cash from Operating Activities
-ÂĄ7.8B
CAGR 3-Years
-15%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Cash from Operating Activities
ÂĄ2.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash from Operating Activities
ÂĄ1.5B
CAGR 3-Years
49%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Cash from Operating Activities
ÂĄ796.9m
CAGR 3-Years
-13%
CAGR 5-Years
9%
CAGR 10-Years
13%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cash from Operating Activities
ÂĄ3.3B
CAGR 3-Years
-29%
CAGR 5-Years
24%
CAGR 10-Years
36%
No Stocks Found

Mabwell Shanghai Bioscience Co Ltd
Glance View

Market Cap
9.2B CNY
Industry
Biotechnology

Mabwell (Shanghai) Bioscience Co., Ltd. engages in the research and development, production and sales of therapeutic biological products. The company is headquartered in Shanghai, Shanghai and currently employs 1,052 full-time employees. The company went IPO on 2022-01-18. The firm's main businesses include the establishment of new varieties of drugs and the discovery of some early projects, the organization and development of preclinical research and pharmacological effects, and the development of drugs for preclinical research. The firm is also engaged in the organization, management and development of clinical trials of research species. The firm's research on drugs covers autoimmune, tumor, metabolism, ophthalmology, infection and other disease fields. The firm conducts business in domestic and foreign markets.

Intrinsic Value
27.94 CNY
Undervaluation 18%
Intrinsic Value
Price
M

See Also

What is Mabwell Shanghai Bioscience Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
-782.7m CNY

Based on the financial report for Dec 31, 2023, Mabwell Shanghai Bioscience Co Ltd's Cash from Operating Activities amounts to -782.7m CNY.

What is Mabwell Shanghai Bioscience Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-38%

Over the last year, the Cash from Operating Activities growth was -9%. The average annual Cash from Operating Activities growth rates for Mabwell Shanghai Bioscience Co Ltd have been -15% over the past three years , -38% over the past five years .

Back to Top